Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/24/2024 | $60.00 | Buy | UBS |
9/23/2024 | $66.00 | Outperform | RBC Capital Mkts |
8/28/2024 | $65.00 | Buy | ROTH MKM |
6/28/2024 | $65.00 | Buy | BofA Securities |
2/20/2024 | $75.00 | Overweight | Cantor Fitzgerald |
2/20/2024 | $42.00 | Neutral | Goldman |
2/20/2024 | $55.00 | Overweight | Morgan Stanley |
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202
IRVINE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that four Trials in Progress Posters highlighting cretostimogene, in addition to the recently announced late breaking abstract on BOND-003, will be presented at the Society of Urologic Oncology (SUO) 25th Annual Meeting taking place at the Sheraton Dallas Hotel in Dallas, TX, from December 4 - 6, 2024. Details on the late-breaking abstract and posters are as follows: Late-Breaking Abstract: Topline Results from BOND
- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the third quarter ended September 30, 2024, and provided business updates. "This quarter, we've continued to make significant advancements across our pipeline to bring forward a potential backbone bladder-spa
– Phase 1b study results were published simultaneously in Nature Medicine and presented at the Society for Immunotherapy of Cancer 2024 – – Encouraging data adds to the body of evidence supporting potential use of cretostimogene as a backbone bladder-sparing therapeutic for bladder cancer – IRVINE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the publication in Nature Medicine of Phase 1b investigator-sponsored study results evaluating intravesical cretostimogene grenadeno
4/A - CG Oncology, Inc. (0001991792) (Issuer)
8-K - CG Oncology, Inc. (0001991792) (Filer)
144 - CG Oncology, Inc. (0001991792) (Subject)
144 - CG Oncology, Inc. (0001991792) (Subject)
9 analysts have expressed a variety of opinions on CG Oncology (NASDAQ:CGON) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 5 2 0 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated CG Oncology and provided 12-month price targets. The average target is $68.33, accompanied by a high estimate of $75.00 and a low estimate of $50.00. This current
B of A Securities analyst Charlie Yang initiates coverage on CG Oncology (NASDAQ:CGON) with a Buy rating and announces Price Target of $65.
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SC 13G - CG Oncology, Inc. (0001991792) (Subject)
UBS initiated coverage of CG Oncology with a rating of Buy and set a new price target of $60.00
RBC Capital Mkts initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $66.00
ROTH MKM initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)
4 - CG Oncology, Inc. (0001991792) (Issuer)